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Compensatory reaction of liver tissue after damage is a typical hepatic response on which
most of modern hepatic surgical therapy relies.1 Characteristic changes in the rate of cellular
proliferation (hyperplasia) and hepatocyte volume (hypertrophy) are observed every time a
part of the liver is removed or whenever an impairment occurs in the blood supply to the
organ (ischemic damage).
Substances which are able to support the liver in those reparative processes or which can
prevent hepatocellular damage from different causes are referred to as hepatotrophic. Using
this definition, hepatotrophic qualities have been associated with several endogenous
substances, including insulin2,3 and cytosolic extract from regenerating livers.4,5 More
recently, a striking hepatotrophic effect has been demonstrated for CyA.6
In this study, the hepatotrophic effects of the new immunosuppressive agent, FK 506, were
tested using an experimental model (Eck-fistula in dogs) that allows hepatocyte renewal and
hypertrophy to be separated.7 The results were then compared with those obtained with CyA
under the same experimental conditions.6
MATERIALS AND METHODS
A functional end-to-side portacaval shunt (Eck-fistula) was created in 21 adult female
beagle dogs weighing 10.5 ± 2.3 kg with the surgical technique previously described6,7 (Fig
1). Different doses of FK 506 were then continuously infused for 4 days into the left branch
of the portal vein. Four group of animals were studied: group 1 (n = 4) received an infusion
of the vehicle used to solubilize FK 506 (HCO-60, polyoxyethilated hydrogenated castrol oil
and D-mannitol) at the rate equivalent to the FK 506 infusion rate of 0.01 mg/kg/d (two
animals) and 1 mg/kg/d (two animals); group 2 (n = 6) received FK 506, 0.01 mg/kg/d for 4
days; group 3 (n = 6) received FK 506, 1 mg/kg/d for 4 days; and group 4 (n = 5) received
FK 506, 1 mg/kg/d for 4 days.
At the end of the infusion period, intravenous [3H]-thymidine was injected 2 hours before
biopsy specimens were obtained from left and right lobes of the liver.
As an index of hepatocyte regeneration, the number of mitosis was determined by counting
the number of [3H]-thymidine-labeled nuclei per 1,000 hepatocytes. The volume of
individual hepatocytes (index of hypertrophy) was determined by determination of
hepatocyte cell size units.2,3
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All data are reported as mean values ± standard deviation (SD). For analysis of variance
(ANOVA), the two main populations were control dogs (receiving only the vehicle) and FK
506-treated dogs. An F test value of >3.0 (P < 0.01) was considered significant. The
comparison between individual experimental groups (differences right/left and CyA/FK
506) was carried out using the Student’s t test. A probability of <0.05 was considered to be
significant.
RESULTS
The positive effect of FK 506 on cell renewal and on restoration of the hepatocyte normal
size is summarized in Tables 1 and 2.
Control Animals
The FK 506 vehicle had no significant effect and the hepatocytes suffered the typical
changes observed after Eck-fistula.7 There were slightly more than 4 mitoses/1,000
hepatocytes. The cells were irregular in shape, depleted of glycogen, and shrunken in size.
The cell size of the hepatocytes of this group ranged between 0.104 and 0.110. The normal
value in dogs is 0.160 ± 0.01 U (Table 2).
FK 506 Infusion
A dose response relation was evident in the increase in mitotic index (Table 1) and the
hepatocyte size (Table 2) in the FK 506-treated dogs. The increased hepatocyte mitoses as
well as the restoration of normal hepatocyte size was most striking in the lobes infused with
FK 506, but there was also a spillover effect to the right lobes.
The right (non-infused) lobes had changes similar to, although less than, those in the left
(infused) lobes (Tables 1 and 2). The results observed with FK 506 were similar to those
previously reported6 with CyA (Table 3), although FK 506 was infused at one fourth to one
sixth of the dose used for CyA. Besides the prevention of cellular atrophy after Eck-fistula,
high-dose FK 506 (1 mg/kg/d) was also able to induce a significantly stronger cell renewal
than that observed with CyA (Table 3).
DISCUSSION
In effect, the Eck-fistula model used in the present studies splits the liver into two fragments
that differ only by what is infused into one of the two main branches of the portal vein.
Therefore, hepatotrophic actions of a given substance can be studied comparing, in the same
liver, hepatocytes from the infused (treated) lobes versus hepatocytes from non-infused
(control) lobes. With this model, the portal route of drug delivery which follows oral
ingestion of CyA or FK 506 was simulated in the left lobes but not in the right lobes.
Hepatic regeneration is augmented by CyA.8–10 In Eck-fistula dogs, CyA prevents
hepatocellular atrophy and restores the normal cellular size and morphology and, in
addition, it augments the low-grade hyperplasia characteristic of this model.6 The effects of
FK 506 are much the same. With both drugs there appear to be no harmful consequences of
delivering the drugs directly to the liver. In fact, the infused (left) lobes exhibited higher
mitotic index and healthier hepatocytes when compared with the control (right) lobes.
There were no statistically significant differences between results obtained with FK 506 and
CyA (Table 3), although FK 506 was infused at one fourth to one sixth the dosage used for
CyA. Therefore, a stronger hepatotrophic effect of FK 506 was present with FK 506 versus
CyA on a molar basis.
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The hepatotrophic (liver-supporting) qualities of FK 506 are in accord with the clinical
observations about the value of this new immunosuppressive agent for salvage of normal
liver grafts which were severely damaged by ischemic and immunologic reactions.11,12
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Fig 1.
Surgical model of Eck-Fistula (portacaval shunt) with external continuous infusion of CyA
and FK 506.
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Table 2
Hepatocyte Size After Intraportal Continuous Infusion of CyA in Eck-fistula Dogs
Group No. No. of Experiments FK 506 Infusion Rate* (mg/kg/d)
Cell Size Units (Mean ± SD)†
Right Lobes Left Lobes
1 4 0 (controls) 0.104 ± 0.018 0.110 ± 0.016
2 6 0.01 0.103 ± 0.074 0.111 ± 0.083
3 6 0.1 0.113 ± 0.081 0.137 ± 0.076
4 5 1 0.134 ± 0.059 0.161 ± 0.011
*
ANOVA (all FK 506 dogs versus controls): F = 20,034, P = 0.001.
†
In normal dogs, hepatocyte size units are 0.160 ± 0.01.2,3,6
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Table 3
Comparison Between Hepatotrophic Qualities of FK 506 and CyA*
Group Comparison
Mitosis Cell Size UnitsFK 506 (mg/kg/d) CyA (mg/kg/d)
Controls v Controls NS NS
0.01 v 0.06 NS NS
0.1 v 0.6 NS NS
1 v 4 <0.003 NS (normal value restored in both treatments)
Note: FK 506 has a hepatotrophic effect more potent than CyA on a molar bases. At high
infusion rate, FK 506 further stimulates the cell renewed component of liver regeneration.
*
Complete data on CyA are reported in reference 6.
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